Evidence map›Paper›PMID 41675675›Full record

ArticleMaterials today. Bio2026

A purpurin-based metalloimmunostimulant amplifies ROS and modulates STING/TNF-α axis to potentiate melanoma immunotherapy.

Xiaoxin Yang, Mi Huang, Tianyi Pang, Dong Zhong, Hong Liu, Xiang Chen, Jun Liu, Yu Wen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoxin YangCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Mi HuangCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Tianyi PangCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Dong ZhongDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Hong LiuCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Xiang ChenCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Jun LiuCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
Yu WenCentral South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The low infiltration of pro-inflammatory immune cells and the sustained activation of multiple immunosuppressive signaling pathways in melanoma significantly limit the efficacy of clinical immunotherapy. Therefore, developing an effective immunostimulant with reversing the immunosuppressive tumor microenvironment (TME) is of great significance for improving melanoma immunotherapy. Herein, a degradable metalloimmunostimulant (PurpN/Mn@PEG) is developed for immunotherapy targeting immunosuppressive melanoma. The PurpN/Mn@PEG NPs are fabricated by coordination-driven self-assembly of purpurin and Mn

Indexed as

MelanomaMetalloimmunostimulantROS amplificationSynergistic immunotherapyTNF-α pathway

Identifiers

PMID41675675
PMCPMC12887887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.